Table 2.
Inflammation-related pathways | CO % | LI % |
Antifolate resistance | 14 | — |
Chemokine signaling | 10 | — |
Cellular senescence | 10 | — |
Fluid shear stress and atherosclerosis | 15 | — |
Non-alcoholic fatty liver disease | 10 | — |
Th17 cell differentiation | 10 | — |
AGE-RAGE signaling (in diabetes) | 15 | 18 |
IL-17 signaling | 25 | 29 |
NF-kappa B signaling | 14 | 19 |
NOD-like receptor signaling | 15 | 22 |
Oxytocin signaling | 17 | 20 |
Rheumatoid arthritis | 14 | 19 |
TNF signaling | 24 | 31 |
Cytokine-cytokine receptor interaction | — | 14 |
Other immune-related pathways | CO % | LI % |
B cell receptor signaling | 15 | — |
Prolactin signaling pathway | 9 | — |
T cell receptor signaling pathway | 10 | — |
Th1 and Th2 cell differentiation | 8 | — |
Cytosolic DNA-sensing | 14 | 23 |
C-type lectin receptor signaling | 17 | 25 |
Toll-like receptor signaling pathway | 11 | 16 |
Leukocyte transendothelial migration | — | 19 |
Oxidative stress-related pathways | CO % | LI % |
FoxO signaling | 12 | — |
HIF-1 signaling | — | 16 |
The non-infection, non-cancer, immune-related KEGG pathways identified as enriched using Fisher’s exact test with Benjamini-Hochberg control (α=0.05). Columns CO % and LI % denote the proportion of genes identified for each pathway by CoNE and LIMMA approaches, respectively